Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Biochemistry

• Publication date

  2005-07-07

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/BI050387OPMID 16042400
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

  2014cited by this paper
• Site‐specific pseudophosphorylation modulates the rate of tau filament dissociation

  2005cited by this paper
• Transcriptional and conformational changes of the tau molecule in Alzheimer's disease.

  2005cited by this paper
• Pathways of tau fibrillization.

  2005cited by this paper
• Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.

  2005cited by this paper
• Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins*

  2005cited by this paper
• Triggers of full-length tau aggregation: a role for partially folded intermediates.

  2005cited by this paper
• The binding of thioflavin-T to amyloid fibrils: localisation and implications.

  2005cited by this paper
• Recent advances in experimental modeling of the assembly of tau filaments.

  2005cited by this paper
• Abeta40-Lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid.

  2005cited by this paper
• Anthraquinones Inhibit Tau Aggregation and Dissolve Alzheimer's Paired Helical Filaments in Vitro and in Cells*

  2005cited by this paper
• Evidence for an intermediate in tau filament formation.

  2004cited by this paper
• The influence of cooperativity on the determination of dissociation constants: examination of the Cheng-Prusoff equation, the Scatchard analysis, the Schild analysis and related power equations.

  2004cited by this paper
• Neuropathological diagnostic criteria for Alzheimer's disease

  2004cited by this paper
• Detailed kinetic studies of an aggregating inhibitor; inhibition of phosphomannomutase/phosphoglucomutase by disperse blue 56.

  2004cited by this paper
• Pseudophosphorylation and Glycation of Tau Protein Enhance but Do Not Trigger Fibrillization in Vitro*

  2004cited by this paper
• Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils.

  2004cited by this paper
• Ligand-dependent inhibition and reversal of tau filament formation.

  2004cited by this paper
• The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils.

  2004cited by this paper
• A static laser light scattering assay for surfactant-induced tau fibrillization.

  2004cited by this paper
• Harnessing Chaperones to Generate Small-Molecule Inhibitors of Amyloid ß Aggregation

  2004cited by this paper
• Electron microscopy as a quantitative method for investigating tau fibrillization.

  2004cited by this paper
• Nucleation-elongation: a mechanism for cooperative supramolecular polymerization.

  2003cited by this paper
• Imaging linear birefringence and dichroism in cerebral amyloid pathologies

  2003cited by this paper
• Pinacyanol as effective probe of fibrillar beta-amyloid peptide: comparative study with Congo Red.

  2003cited by this paper
• Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics

  2003cited by this paper
• Congo Red Populates Partially Unfolded States of an Amyloidogenic Protein to Enhance Aggregation and Amyloid Fibril Formation*

  2003cited by this paper
• Anionic Micelles and Vesicles Induce Tau Fibrillization in Vitro*

  2003cited by this paper
• A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.

  2002cited by this paper
• Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay

  2002cited by this paper
• Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease.

  2002cited by this paper
• Surface-catalyzed Amyloid Fibril Formation*

  2002cited by this paper
• Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments.

  2002cited by this paper
• Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct

  2001cited by this paper
• Structural analysis of Pick's disease-derived and in vitro-assembled tau filaments.

  2001cited by this paper
• Is Congo Red an Amyloid-specific Dye?*

  2001cited by this paper
• Designing drugs to stop the formation of prion aggregates and other amyloids.

  2000cited by this paper
• In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants.

  2000cited by this paper
• Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice.

  2000cited by this paper
• Oxidative regulation of fatty acid-induced tau polymerization.

  2000cited by this paper
• Cyanine Dyes as Protectors of K562 Cells from Photosensitized Cell Damage†

  2000cited by this paper
• Quantification of beta-sheet amyloid fibril structures with thioflavin T.

  1999cited by this paper
• Tangled areas of Alzheimer brain have upregulated levels of exon 10 containing tau mRNA.

  1999cited by this paper
• Ligand-dependent tau filament formation: implications for Alzheimer's disease progression.

  1999cited by this paper
• Selective staining by the fluorochrome, 5,5-diphenyl-9-ethyl-DiOC2(3). I. Physicochemical studies of dye-dye and dye-tissue interactions.

  1999cited by this paper
• A model for structure-dependent binding of Congo red to Alzheimer beta-amyloid fibrils.

  1998cited by this paper
• Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution.

  1998cited by this paper
• A nucleated assembly mechanism of Alzheimer paired helical filaments.

  1998cited by this paper
• Acute Inactivation of Tau Has No Effect on Dynamics of Microtubules in Growing Axons of Cultured Sympathetic Neurons

  1998cited by this paper
• Alzheimer-like Changes in Microtubule-associated Protein Tau Induced by Sulfated Glycosaminoglycans

  1997cited by this paper
• Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease.

  1997cited by this paper
• Early contribution of oxidative glycation in Alzheimer disease.

  1996cited by this paper
• Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction.

  1996cited by this paper
• RNA stimulates aggregation of microtubule‐associated protein tau into Alzheimer‐like paired helical filaments

  1996cited by this paper
• Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments.

  1996cited by this paper
• The Structural Basis of Monoclonal Antibody Alz50's Selectivity for Alzheimer's Disease Pathology*

  1996cited by this paper
• Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.

  1995cited by this paper
• Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion.

  1995cited by this paper
• Band-shifting through polypeptide beta-sheet structures in the cyanine UV-Vis spectrum.

  1995cited by this paper
• Altered microtubule organization in small-calibre axons of mice lacking tau protein

  1994cited by this paper
• Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution

  1993cited by this paper
• The Cheng-Prusoff relationship: something lost in the translation.

  1993cited by this paper
• Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

  1992cited by this paper
• ALZHEIMER'S DISEASE: PAIRED HELICAL FILAMENTS AND CYTOMEMBRANES

  1987cited by this paper
• The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

  1961cited by this paper
• [Analysis of dyes; fluorochrome mixture thioflavine S].

  1955cited by this paper

• Plant-Based Inhibitors of Protein Aggregation

  2025cites this paper
• Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies

  2025cites this paper
• 4-Amino-3',4'-dihydroxychalcone Increases Tau Dynamics in Phase-Separated Droplets and Inhibits Tau Aggregation.

  2025cites this paper
• Aggregation inhibitors of tau protein with anti-inflammatory potential against neurodegeneration.

  2025cites this paper
• Discovery of small molecule benzothiazole and indole derivatives tackling tau 2N4R and α-synuclein fibrils

  2024cites this paper
• Sedimentation and Laser Light Scattering Methods for Quantifying Synthetic Tau Aggregation Propensity.

  2024cites this paper
• Small-molecule theranostics in Alzheimer's disease.

  2023cites this paper
• Thioxanthenone-based derivatives as multitarget therapeutic leads for Alzheimer's disease.

  2023cites this paper
• Fisetin inhibits tau aggregation by interacting with the protein and preventing the formation of β-strands.

  2021cites this paper
• C1 Inhibits Liquid-Liquid Phase Separation and Oligomerization of Tau and Protects Neuroblastoma Cells against Toxic Tau Oligomers.

  2021cites this paper
• Chemoinformatics Analyses of Tau Ligands Reveal Key Molecular Requirements for the Identification of Potential Drug Candidates against Tauopathies

  2021cites this paper
• Sulfur-containing therapeutics in the treatment of Alzheimer’s disease

  2021cites this paper
• Utilisation of the OliveNet™ Library to investigate phenolic compounds using molecular modelling studies in the context of Alzheimer's disease

  2020cites this paper
• Tau Protein Aggregation in Alzheimer's Disease: Recent advances in the development of novel therapeutic agents.

  2020cites this paper
• Basic Limonoid modulates Chaperone-mediated Proteostasis and dissolve Tau fibrils

  2020cites this paper
• Promising Molecular Targets for Pharmacological Therapy of Neurodegenerative Pathologies

  2020cites this paper
• Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance.

  2020cites this paper
• Photodynamic exposure of Rose-Bengal inhibits Tau aggregation and modulates cytoskeletal network in neuronal cells

  2020cites this paper
• Understanding the disrupting mechanism of the Tau aggregation motif "306 VQIVYK311 " by phenylthiazolyl-hydrazides inhibitors.

  2020cites this paper
• Cyanine dyes derived inhibition of insulin fibrillization

  2019cites this paper
• Neem Derivatives Inhibits Tau Aggregation1

  2019cites this paper
• Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer's Disease.

  2019cites this paper
• Xanthohumol inhibits tau protein aggregation and protects cells against tau aggregates.

  2019cites this paper
• Perspectives on drug discovery strategies based on IDPs

  2019cites this paper
• Targeting Amyloid Aggregation: An Overview of Strategies and Mechanisms

  2018cites this paper
• Amyloids of multiple species: are they helpful in survival?

  2018cites this paper
• Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.

  2017cites this paper
• Curcumin Inhibits Tau Aggregation and Disintegrates Preformed Tau Filaments in vitro

  2017cites this paper
• The Molecular Chaperone Artemin Efficiently Blocks Fibrillization of TAU Protein In Vitro

  2017cites this paper
• Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

  2016cites this paper
• Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

  2016influential citation
• Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease

  2016cites this paper
• Targeting Assembly and Disassembly of Protein Aggregates

  2015cites this paper
• Inhibition of Alzheimer’s type toxic aggregates of tau with fungal secondary metabolites

  2015cites this paper
• Tau Protein Associated Inhibitors in Alzheimer Disease

  2014cites this paper
• Structure and mechanism of action of tau aggregation inhibitors.

  2014cites this paper
• Inhibition of Tau Aggregation by Three Aspergillus nidulans Secondary Metabolites: 2,ω-Dihydroxyemodin, Asperthecin, and Asperbenzaldehyde

  2014cites this paper
• Progress and developments in tau aggregation inhibitors for Alzheimer disease.

  2013cites this paper
• Structural Determinants of Tau Aggregation Inhibitor Potency*

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

  2013cites this paper
• Potential synergy between tau aggregation inhibitors and tau chaperone modulators

  2013cites this paper
• Targeting Tau Aggregation for the Diagnosis and Treatment of Alzheimer's Disease

  2013cites this paper
• The Role of Aβ and Tau Oligomers in the Pathogenesis of Alzheimer’s Disease

  2012cites this paper
• QSAR studies for prediction of cross-β sheet aggregate binding affinity and selectivity.

  2012cites this paper
• Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

  2012cites this paper
• Rational Optimization of Small Molecules for Alzheimer’s Disease Premortem Diagnosis

  2012cites this paper
• Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease

  2012cites this paper
• Natural products as a rich source of tau-targeting drugs for Alzheimer's disease.

  2012cites this paper
• Influence of Phosphorylation on the Pathological Conformation of Human Microtubule Associated Protein Tau

  2012cites this paper
• Tau as a therapeutic target in neurodegenerative disease.

  2012cites this paper
• Molecules of the Quinoline Family Block Tau Self-Aggregation: Implications Toward a Therapeutic Approach for Alzheimer's Disease

  2012cites this paper
• Ligand electronic properties modulate tau filament binding site density.

  2012cites this paper
• Alzheimer's disease: emerging trends in small molecule therapies.

  2011cites this paper
• Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.

  2011cites this paper
• Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.

  2011cites this paper
• Tau as a therapeutic target for Alzheimer's disease.

  2011cites this paper
• Utilisation de colorants cyanine pour la détection de tau pour le diagnostic de tauopathies de stade précoce

  2011cites this paper
• Tau phosphorylation and aggregation as a therapeutic target in tauopathies.

  2010cites this paper
• Non-amyloid Approaches To Alzheimer's Disease

  2010cites this paper
• In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models.

  2010cites this paper
• Tau protein and tau aggregation inhibitors.

  2010influential citation
• 3D QSAR CoMFA Study on Phenylthiazolylhydrazide (PTH) Derivataives as Tau Protein Aggregation Inhibitors

  2010cites this paper
• Disaggregation of tau as a therapeutic approach to tauopathies.

  2010cites this paper
• Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.

  2010cites this paper
• Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles

  2009cites this paper
• Structure-activity relationship of cyanine tau aggregation inhibitors.

  2009cites this paper
• Entwicklung von Inhibitoren der Tau‐Aggregation bei Morbus Alzheimer

  2009cites this paper
• [Fundamental data on the pathologies amyloid and Tau in Alzheimer's disease: which therapeutic perspectives?].

  2009cites this paper
• Données fondamentales sur les pathologies amyloïde et Tau dans la maladie d’Alzheimer : quelles perspectives thérapeutiques ?

  2009cites this paper
• Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau

  2009cites this paper
• Inhibition of Tau Polymerization with a Cyanine Dye in Two Distinct Model Systems*

  2009cites this paper
• Chaperone-Like Antibodies in Neurodegenerative Tauopathies: Implication for Immunotherapy

  2009cites this paper
• Tau aggregation: role in neurodegeneration and inhibition with small molecules

  2009cites this paper
• Development of tau aggregation inhibitors for Alzheimer's disease.

  2009cites this paper
• Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.

  2009cites this paper
• Nucleation-dependent Tau Filament Formation

  2008cites this paper
• Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain.

  2008cites this paper
• Chaperone-like Antibodies Targeting Misfolded Tau Protein: New Vistas in the Immunotherapy of Neurodegenerative Foldopathies

  2008cites this paper
• Hyperphosphorylation and mutation enhance Tau aggregation.

  2008cites this paper
• Amyloid ß-derived switch-peptides as tool to study conformational changes relevant in degenerative diseases

  2008cites this paper
• Conformation of Human Microtubule Associated Protein-Tau

  2008cites this paper
• Tau-based treatment strategies in neurodegenerative diseases

  2008cites this paper
• Anti-Aβ1–11 Antibody Binds to Different β-Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers*

  2007cites this paper
• Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

  2007cites this paper
• Marked difference between self-aggregations of first and fourth repeat peptides on tau microtubule-binding domain in acidic solution.

  2007cites this paper
• Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization.

  2007cites this paper
• Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct*

  2007cites this paper
• Effect of DNA on filament formation of tau microtubule-binding domain: structural dependence of DNA.

  2007cites this paper
• Potent inhibition of tau fibrillization with a multivalent ligand.

  2007cites this paper
• Potency of a tau fibrillization inhibitor is influenced by its aggregation state.

  2007cites this paper
• Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers.

  2007cites this paper
• A complex mechanism for inducer mediated tau polymerization.

  2007cites this paper
• Tauopathie et maladie d’Alzheimer, un processus dégénératif à part entière

  2006cites this paper
• Spectroscopic Approaches to the Conformation of Tau Protein in Solution and in Paired Helical Filaments

  2006cites this paper
• Self-assembly of fibers and fibrils.

  2006cites this paper
• Selbstorganisation von Fasern und Fibrillen

  2006cites this paper
• Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics

  2006cites this paper
• [Tauopathy and Alzheimer disease: a full degenerating process].

  2006cites this paper
• Characterization of two VQIXXK motifs for tau fibrillization in vitro.

  2006cites this paper
• Current strategies for the treatment of Alzheimer’s disease and other tauopathies

  2006cites this paper